Pfizer and BioNTech announced that they have begun vaccine trials in pregnant participants aged 18 years and older. They write, “We are proud to start this study in pregnant women and continue to gather the evidence on safety and efficacy to potentially support the use of the vaccine by important subpopulations.”
In total, they plan to enroll 4,000 healthy pregnant participants during 24–34 weeks of gestation.
The press release outlines the importance of this research: “Pregnant women have an increased risk of complications and developing severe COVID-19, which is why it is critical that we develop a vaccine that is safe and effective for this population. We are deeply thankful to the volunteers who are enrolling in the trial and site investigators who are leading this work.